medigraphic.com
ISSN 2683-1678 (Print)
Órgano Oficial de la Sociedad
Latinoamericana de lnfectología Pediátrica.
Órgano de la Asociación Mexicana de
Infectología Pediátrica, A.C.
Órgano difusor de la Sociedad Española
de lnfectología

2020, Number 4

<< Back Next >>

Rev Latin Infect Pediatr 2020; 33 (4)

SARS-CoV-2 (COVID-19) infection in pediatrics

Rodríguez HR, Rivera DM, Huante AA

Language: Spanish
References: 69
Page: 191-203
PDF size: 288.58 Kb.


ABSTRACT

The infection due to coronavirus is a global emergency. During the last months, the fastest increase in the number of cases and deaths by this cause has occurred, especially in older people and those who suffer from hypertension, diabetes, obesity, and other chronic diseases, the severity of the symptoms in children and adolescents is less and the mortality is really low, but those immersed in a state of immunosuppression, undernourishment, medical comorbidities, and the lack of hygiene have a bigger risk of developing the infection. The reduction of these risk factors and adopting the proper preventive measures will be helpful in order to limit the spread since today there is no effective treatment or specific immunization for treating this serious problem. This revision stands out the problems and challenges of the infection caused by SARS-CoV-2 in children and adolescents.


REFERENCES

  1. Shen K, Yang Y, Wang T, Zhao D, Jiang Y, Jin R et al. Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts consensus statement. World J Pediatr. 2020; 16: 223-231. Available in: http://dx.doi.org/10.1007/s12519-020-00343-7.

  2. Chen ZM, Fu JF, Shu Q, Chen YH, Hua CZ, Li FB et al. Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. World J Pediatr. World J Pediatr. 2020; 16 (3): 240-246. Available in: http://dx.doi.org/10.1007/s12519-020-00345-5.

  3. Yan R, Qing D , Zhong S, Yuan Y, Shou D , Hong J et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-an update on the status. Mil Med Res. 2020; 7 (1): 11. Available in: https://doi.org/10.1186/s40779-020-00240-0.

  4. Kuldeep D, Khan S, Ruchi T, Maryam D, Yashpal S et al. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Hum Vaccin Immunother. 2020; 16 (6): 1232-1238. doi: 10.1080/21645515.2020.1735227.

  5. Yang Y, Md S, Jin W, Yuan L, Xin C. Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective. Int J Biol Sci. 2020; 16 (10): 1708-1717. doi: 10.7150/ijbs.45538.

  6. American Academy of Pediatrics. Children and COVID-19: state level data report. Available in: https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/.

  7. Yang P, Liu P, Li D, Zhao D. Corona virus disease 2019, a growing threat to children? J Infect. 2020; 80 (6): 671-693. Advance online publication. Available in: https://doi.org/10.1016/j.jinf.2020.02.024.

  8. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 2020b; 395 (10226): 809-815. [Cited 2020 Mar 23]. Available in: http://www.sciencedirect.com/science/article/pii/S0140673620303603.

  9. Lu Q, Shi Y. Coronavirus disease (COVID-19) and neonate: what neonatologist need to know. J Med Virol. 10.1002/jmv.25740. Advance online publication. https://doi.org/10.1002/ jmv.25740. [Cited 2020 Mar 23]. https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25740.

  10. Cruz AT, Zeichner SL. COVID-19 in children: initial characterization of the pediatric disease. Pediatrics. 2020; 145 (6): e20200834.

  11. Kam K, Yung CF, Cui L, Lin Tzer Pin R, Mak TM, Maiwald M et al. A well infant with coronavirus disease 2019 (COVID-19) with high viral load. Clin Infect Dis. 2020; 71 (15): 847-849. Advance online publication. https://doi.org/10.1093/cid/ciaa201. [Cited 2020 Mar 23]. https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa201/5766416. doi: 10.1093/cid/ciaa201.

  12. Asociación Española de Pediatría en Atención Primaria. Manejo del paciente pediátrico ante la sospecha de infección por el nuevo coronavirus SARS-CoV-2 en Atención Primaria (COVID-19) AEPap-SEIP/AEP-SEPEAP. Disponible en: https://www.aepap.org/sites/default/files/noticia/archivosadjuntos/2020_04_07_covid_ap.pdf.

  13. Jonas F. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020; [Online ahead of print] PMID: 32202343. doi: 10.1111/apa.15270.

  14. Yuanyuan D, Xi M, Yabin H, Xin Q, Fan J et al. Epidemiology of COVID-19 among children in China. Pediatrics. 2020; 145 (6): e20200702. doi: https://doi.org/10.1542/peds.2020-0702.

  15. Wenhui L, Michael J, Natalya V, Jianhua S, Swee K et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003; 426 (6965): 450-544. PMID: 14647384, PMCID: PMC7095016, doi: 10.1038/nature02145.

  16. Hussin A, Siddappa N. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020; 109: 102433. Online ahead of print] PMID: 32113704 PMCID: PMC7127067, doi: 10.1016/j.jaut.2020.102433.

  17. CDC COVID-19 Response Team. Coronavirus Disease 2019 in Children-United StatesFebruary 12-April 2, 2020. Morbidity and Mortality Weekly Report 422 MMWR.

  18. Ying-H, Lin C, Zhen-Shun CH, Hong C, Tong D, Yi-Pin F et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020; 7: 4. PMID: 3202900PMCID: PMC7003341, doi: 10.1186/s40779-020-0233-6.

  19. Yun-Yun W, Ying-Hui J, Xue-Qun R, Yi-Rong L, Xiao-Chun Z, Xian-Tao Z et al. Updating the diagnostic criteria of COVID19 “suspected case” and “confirmed case” is necessary. Mil Med Res. 2020; 7 (1): 17. PMID: 32245396 PMCID: PMC7125052, doi: 10.1186/s40779-020-00245-9.

  20. Zheng Ye, Yun Zhang, Yi Wang, Zixiang Huang, Bin Song. Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review. Eur Radiol. 2020; 30: 4381-4389. Available in: https://doi.org/10.1007/s00330-020-06801-0.

  21. Tao A, Zhenlu Y, Hongyan H, Chenao Z, Chong C, Wenzhi L et al. Correlation of Chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1,014 cases. Radiology. 2020; 296 (2): E33-340. [Online ahead of print] PMID: 32101510, doi: 10.1148/radiol.2020200642.

  22. AEMPS. Agencia española de Medicamentos y Productos Sanitarios. Tratamientos disponibles para el manejo de la infección respiratoria por SARS-CoV-2. Available in: https://www.aemps.gob.es/.

  23. Bin C, Yeming W, Danning W, Wen L, Jingli W. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med. 2020; 382: 1787-1799. doi: 10.1056/NEJMoa2001282.

  24. WHO. “Solidarity” clinical trial for COVID-19 treatments. Available in: https://www.who.int/emergencies/diseases/novel-coronavirus-2019.

  25. Mulangu S, Dodd LE, Davey RT Jr., Tshiani MO, Proschan M, Mukadi D et al. A randomized, controlled trial of ebola virus disease therapeutics. N Engl J Med. 2019; 381 (24): 2293-2303. doi: 10.1056/NEJMoa1910993.

  26. Cao YC, Deng QX, Dai SX. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence. Travel Med Infect Dis. 2020; 35: 101647. doi: 10.1016/j.tmaid.2020.101647.

  27. Zhonghua J, He H, Xi Za Z. Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]. 2020;43 (3): 185-188. Chinese. doi: 10.3760/cma.j.issn.1001-0939.2020.03.009. PMID: 32164085.

  28. World Health Organization. WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19. Available in: https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19.

  29. Ohe M, Shida H, Jodo S, Kusunoki Y, Seki M, Furuya K et al. Macrolide treatment for COVID-19: will this be the way forward?. Biosci Trends. 2020; 14 (2): 159-160. doi: 10.5582/bst.2020.03058.

  30. Fu B, Xu X, Wei H. Why tocilizumab could be an effective treatment for severe COVID-19? J Transl Med. 2020; 18 (1): 164. Published 2020; 18: 164. doi: 10.1186/s12967-020-02339-3.

  31. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents. 2020; 55 (5): 105954. doi: 10.1016/j.ijantimicag.2020.105954.

  32. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol. 2020; 92 (7): 814-818. doi: 10.1002/jmv.25801.

  33. Rosa SGV, Santos WC. Clinical trials on drug repositioning for COVID-19 treatment. Rev Panam Salud Publica. 2020; 44: e40. Available in: https://doi.org/10.26633/RPSP.2020.40.

  34. Lythgoe P, Middleton P. Ongoing clinical trials for the management of the COVID-19 pandemic. Trends Pharmacol Sci. 2020; 41 (6): 363-382.

  35. Li W, Shen A, Ling W, Tanaka Y, Zhanga W. TMPRSS2: a potential target for treatment of influenza virus and coronavirus infections. Biochimie. 2017; 142: 1-10.

  36. Steinmetzer T, Hardes K. The antiviral potential of host protease inhibitors. Activation of Viruses by Host Proteases. 2018; 279-325. doi: 10.1007/978-3-319-75474-1_11.

  37. Laporte M, Naesens L. Airway proteases: an emerging drug target for influenza and other respiratory virus infections. Curr Opin Virol. 2017; 24: 16-24. doi: 10.1016/j.coviro.2017.03.018.

  38. Maggini S, Pierre, Calder A. Immune function and micronutrient requirements change over the life course. Nutrients. 2018; 10 (10): 1531.

  39. Aartjan J, Sjoerd H, Van den W, Amy C, Ralph S, Eric J, Martijn J. Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PLoS Pathog. 2010; 6 (11): e1001176. doi: 10.1371/journal.ppat.1001176.

  40. Gupta R, Ghosh A, Singh AK, Misra A. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes Metab Syndr. 2020; 14 (3): 211-212. doi: 10.1016/j.dsx.2020.03.002.

  41. Wrobel J, Power R, Toborek M. Biological activity of selenium: revisited. IUBMB Life. 2016; 68 (2): 97-105. doi: 10.1002/iub.1466.

  42. Rayman M. Selenium and human health. Lancet. 2012; 379 (9822): 1256-1268. doi: 10.1016/S0140-6736(11)61452-9.

  43. Holger S, Saleh A, Mohamed A, Frank, Helmut S. Dietary selenium in adjuvant therapy of viral and bacterial infections. Adv Nutr. 2015; 6 (1): 73-82. Available in; https://doi.org/10.3945/an.114.007575.

  44. Carr A. A new clinical trial to test high-dose vitamin C in patients with COVID-19. Crit Care. 2020; 24 (1): 133. doi: 10.1186/s13054-020-02851-4.

  45. Grand W, Lahore H, McDonnell S, Baggerly C, French C, Aliano J et al. Nutrients. Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Nutrients. 2020; 12 (4): 988. doi: 10.3390/nu12040988.

  46. Jakovac H. COVID-19 and vitamin D-is there a link and an opportunity for intervention? Am J Physiol Endocrinol Metab. 2020; 318 (5): E589. doi: 10.1152/ajpendo.00138.2020.

  47. Zhang R, Wang X, Ni L, Di X, Ma B, Niu S, Liu C. COVID-19: Melatonin as a potential adjuvant treatment. Life Sci. 2020; 250: 117583. doi: 10.1016/j.lfs.2020.117583.

  48. Habtemariam S, Daglia M, Sureda A, Selamoglu Z, Gulhan MF, Nabavi S. Melatonin and respiratory diseases: a review. Curr Top Med Chem. 2017; 17 (4): 467-488.

  49. Sodhi M, Etminan M. Therapeutic potential for tetracyclines in the treatment of COVID-19. Pharmacotherapy. 2020; doi: 10.1002/phar.2395.

  50. Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. Clin Immunol. 2020; 214: 108393. doi: 10.1016/j.clim.2020.108393.

  51. Qing Y, Wang B, Mao J. Cytokine storm in COVID19 and treatment. Journal of Infection. 2020; 80 (6): 607-613. doi: https://doi.org/10.1016/j.jinf.2020.03.037.

  52. Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol. 2020; 127: 104362. doi: 10.1016/j.jcv.2020.104362.

  53. Carsana L, Sonsogni A, Nars A, Rossi R, Pellegrinelli A, Zerbi P et al. Pulmonary post-mortem findings in a large series of COVID-19 cases from Northern Italy. MedRxiv 2020.04.19.20054262; doi: https://doi.org/10.1101/2020.04.19.20054262.

  54. Li T, Lu H, Zhang W. Clinical observation and management of COVID-19 patients. Emerg Microbes Infect. 2020; 9 (1): 687-690. doi: 10.1080/22221751.2020.174132.

  55. Li T. Diagnosis and clinical management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: an operational recommendation of Peking Union Medical College Hospital (V2.0). Emerg Microbes Infect. 2020; 9 (1): 582-585. doi: 10.1080/22221751.2020.1735265.

  56. Marik P. EVMS. Critical care Covid-19 management protocol. Eastern Virginia Medical School, Norfolk, VA April 15th 2020. EVMS COVID. Available in: https://www.evms.edu/covid-19/medical_information_resources/.

  57. Centers for Disease Control and Prevention (2020) Coronavirus disease 2019 (COVID-19). Centers for Disease Control and Prevention. [Cited 2020 Mar 22]. https://www.cdc.gov/Coronavirus/2019ncov/faq.html?CDC_AA_refVal.https%3A%2F%2Fwww.cdc.gov%2FCoronavirus%2F2019-ncov%2Fprepare%2Fchildren-faq.html#school-dismissals.

  58. Lineamientos para la prevención, detección y atención de Covid-19 en niñas, niños y adolescentes (NNA) Secretaría de Salud. México. Disponible en: https://coronavirus.gob.mx/wpcontent/uploads/2020/05/Lineamientos_prevencion_deteccion_atencion_COVID_NNA-1.pdf.

  59. Wu JT, Leung K, Bushman M, Kishore N, Niehus R, De Salazar PM et al. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nat Med. 2020a; 26 (4): 506-510. https://doi.org/10.1038/s41591-020-0822-7. Available in: https://www.nature.com/articles/s41591-020-0822-7.

  60. Wu D, Wu T, Liu Q, Yang Z. The SARS-CoV-2 outbreak: what we know. Int J Infect Dis. 2020b; https://doi.org/10.1016/j.ijid.2020.03.004 [Cited 2020; 94: 44-48. https://www.ijidonline.com/article/S1201-9712(20)30123-5/abstract.

  61. Xia W, Shao J, Guo Y, Peng X, Li Z, Hu D. Clinical and CT features in pediatric patients with COVID-19 infection: different points from adults. Pediatr Pulmonol. 2020; 55 (5): 1169-1174. Available in: https://doi.org/10.1002/ppul.24718. Available in: https://onlinelibrary.wiley.com/doi/ abs/10.1002/ppul.24718.

  62. Shailendra KS. Epidemiology, pathogenesis, diagnosis, and therapeutics. Coronavirus disease. 2019 (Covid-19). ISBN 978-981-15-4813-0 ISBN 978-981-15-4814-7 (eBook) https://doi.org/10.1007/978-981-15-4814-7.

  63. Wu R, Wang L, Dina KH, Shannar A, Peter R, Chou PJ et al. An update on current therapeutic drugs treating COVID-19. Curr Pharmacol Rep. 2020; 1-15. doi: 10.1007/s40495-020-00216-7.

  64. Sharun K, Dhama K, Patel SK, Pathak M, Tiwari R, Raj SB et al. Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. Ann Clin Microbiol Antimicrob. 2020; 19 (1): 23. doi: 10.1186/s12941-020-00368-w.

  65. Amit N, Patel M, Sapan S, Desai M, David W, Grainger. Mandeep R, Mehra M. Usefulness of ivermectin in COVID-19 illness. Available in: https://www.intramed.net/contenidover.asp?contenidoid=96116.

  66. Paraluppi V, Pintus MC, Fanos V, Marcialis MA. COVID-19 in newborns and in children: the state of the art. J Ped Neonat Individual Med [Internet]. 2020Mar.28 [cited 2020Oct.16];9(1):e090138. Available from: https://jpnim.com/index.php/jpnim/article/view/090138

  67. Zhang L, Liu Y. Potential interventions for novel coronavirus in China: a systemic review. J Med Virol. 2020; 92 (5): 479-490.

  68. Carlotti APCP, Carvalho WB, Johnston C, Rodriguez IS, Delgado AF. COVID-19 diagnostic and management protocol for pediatric patients. Clinics (Sao Paulo). 2020; 75: e1894. doi:10.6061/clinics/2020/e1894.

  69. Dayal D. We urgently need guidelines for managing COVID-19 in children with comorbidities Acta Paediatr. 2020; 10.1111/apa.15304. doi: 10.1111/apa.15304.




2020     |     www.medigraphic.com